The effectiveness of enoxaparin in preventing deep vein thrombosis

Evaluation of the effectiveness of enoxaparin in preventing the occurrence of deep vein thrombosis in patients' candidates for laparoscopic cholecystectomy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210602051484N1

Enrollment

200

Registered

2021-08-10

Start date

2021-06-20

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein thrombosis. Phlebitis and thrombophlebitis of other deep vessels of lower extremities

Interventions

Intervention 1: In the intervention group, in addition to routine treatments, injectable enoxaparin 4000 units, made by Alborz Drug Company, single dose, half an hour before surgery, in the operating

Eligibility

Sex/Gender

All

Age

No minimum to 70 Years

Inclusion criteria

Inclusion criteria: Willingness to participate in the study All patients under 70 years of age do not have coagulation disorders Not having underlying diseases associated with DVT All patients have symptomatic gallstones (abdominal pain, nausea and vomiting after eating) Simultaneous existence of gallbladder polyps and gallstones Diabetic people with gallstones Patients with asymptomatic gallstones who are unable to access equipped centers in the future. Patients who have not allergy to enoxaparin. Do not take anti-coagulant drugs

Exclusion criteria

Exclusion criteria: Patients with surgical indications with the possibility of absolute rest after surgery Patients with the possibility of complications such as postoperative bleeding

Design outcomes

Primary

Measure	Time frame
Not occurrence of deep vein thrombosis. Timepoint: The effectiveness of enoxaparin in 24 hours after injection, 72 hours after injection and 14 days after injection. Method of measurement: Presence or absence of deep vein thrombosis examination and follow-up with color Doppler ultrasound and entering its information in a checklist.;Not occurrence of pulmonary embolism. Timepoint: The effectiveness of enoxaparin in 24 hours after injection, 72 hours after injection and 14 days after injection. Method of measurement: Presence or absence of pulmonary embolism by examination and follow-up with CT pulmonary angiography with venous contrast and entering its information in a checklist.	—

Measure

Time frame

Not occurrence of deep vein thrombosis. Timepoint: The effectiveness of enoxaparin in 24 hours after injection, 72 hours after injection and 14 days after injection. Method of measurement: Presence or absence of deep vein thrombosis examination and follow-up with color Doppler ultrasound and entering its information in a checklist.;Not occurrence of pulmonary embolism. Timepoint: The effectiveness of enoxaparin in 24 hours after injection, 72 hours after injection and 14 days after injection. Method of measurement: Presence or absence of pulmonary embolism by examination and follow-up with CT pulmonary angiography with venous contrast and entering its information in a checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Mohammadiarbati

Zanjan University of Medical Sciences

mohammadarbati@zums.ac.ir009833130000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026